Tripp Levy PLLC Investigates Buyout Of Abraxis BioSciences
Tripp Levy PLLC announces an investigation into the purchase of Abraxis BioSciences Inc. ("Abraxis" or the "Company") (NasdaqGS: ABII) by Celgene Corporation ("Celgene") (NasdaqGS: CELG). Under the terms of the proposed transaction, Abraxis shareholders will receive $58 in cash and 0.2617 shares of Celgene stock for each Abraxis share they own. Based on the prior closing price of Celgene shares, the transaction values Abraxis stock at approximately $71.93 per share for a total transaction value of approximately $2.9 billion, net of cash. Each Abraxis share will also receive one tradeable contingent value right which entitles its holder to receive payments for future regulatory milestones and commercial royalties.
The investigation concerns, among other things, whether the consideration to be paid to Abraxis shareholders is grossly unfair, inadequate, and substantially below the fair or inherent value of Abraxis. The investigation further concerns whether the directors of Abraxis may have breached their fiduciary duties by not acting in Abraxis shareholders' best interests in connection with the sale process of Abraxis.
If you own Abraxis common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact
Tripp LevyTripp Levy PLLC125 East 82 nd Street9 th FloorNew York, New YorkToll Free: 877-772-3975Email: firstname.lastname@example.orgTripp Levy PLLC is a national law firm that specializes in mergers & acquisitions, takeover litigation, shareholder rights, and corporate governance matters in state and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV